The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 08, 2025

Filed:

Feb. 16, 2024
Applicant:

I2o Therapeutics, Inc., Cambridge, MA (US);

Inventors:

Tyler Brown, Cambridge, MA (US);

Kelly Ibsen, Boston, MA (US);

Assignee:

I2O THERAPEUTICS, INC., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/26 (2006.01); A61K 9/08 (2006.01); A61K 31/14 (2006.01); A61K 38/22 (2006.01); A61K 47/12 (2006.01); A61K 47/18 (2017.01); A61K 47/54 (2017.01); A61K 47/68 (2017.01); C07K 14/575 (2006.01); C07K 14/605 (2006.01); C07K 16/24 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/26 (2013.01); A61K 9/08 (2013.01); A61K 31/14 (2013.01); A61K 38/22 (2013.01); A61K 47/12 (2013.01); A61K 47/18 (2013.01); A61K 47/183 (2013.01); A61K 47/186 (2013.01); A61K 47/542 (2017.08); A61K 47/6845 (2017.08); C07K 14/575 (2013.01); C07K 14/605 (2013.01); C07K 16/241 (2013.01); A61K 38/00 (2013.01); C07K 2317/24 (2013.01);
Abstract

Provided herein are compositions comprising a first compound having the structure of first Formula Ia, wherein the first compound comprises a first therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the first compound has an anion: cation molar ratio of from about 1:1 to about 1:3, and a second compound having the structure of second Formula Ia, wherein the second compound comprises a second therapeutic agent having the sequence of SEQ ID NO: 35, and the second compound has an anion: cation molar ratio of from about 1:1 to about 1:7, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.


Find Patent Forward Citations

Loading…